{
  "url": "https://struct.news/briefs/axsomes-revenue-jumped-46-its-six-month-loss-still-got-bigger",
  "title": "Axsome's revenue jumped 46%. Its six-month loss still got bigger.",
  "summary": "Operating cash outflow improved to $53.7M, but inventory more than doubled as commercialization expanded.",
  "published_at": "2026-08-10T20:16:45.068530+00:00",
  "publisher": "Struct",
  "usage": "Figures are as reported by the company. Quote with attribution to the source filing.",
  "company": {
    "name": "Axsome Therapeutics, Inc.",
    "ticker": "AXSM",
    "cik": "1193125",
    "sector": "Healthcare",
    "industry": "Biotechnology"
  },
  "source_filing": {
    "form": "10-Q",
    "filed": "2026-08-10",
    "accession": "0001193125-26-342360",
    "url": "https://www.sec.gov/Archives/edgar/data/1579428/000119312526342360/axsm-20260630.htm"
  },
  "comparison_filing": {
    "form": "10-Q",
    "filed": "2025-08-04",
    "url": "https://www.sec.gov/Archives/edgar/data/1579428/000095017025102148/axsm-20250630.htm"
  },
  "reported_figures": [
    {
      "group": "The filing in three numbers",
      "label": "Revenue",
      "value": 638496000,
      "display": "$638.5M",
      "unit": "usd",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "sec_filing",
        "label": "Filed company results",
        "form": "10-Q",
        "accession": "0001193125-26-342360",
        "filing_date": "2026-08-10"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Revenue YoY",
      "value": 65.54513563896674,
      "display": "+65.5%",
      "unit": "percent",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001193125-26-342360",
        "filing_date": "2026-08-10"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Operating margin",
      "value": -26.117939658196764,
      "display": "-26.1%",
      "unit": "percent",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001193125-26-342360",
        "filing_date": "2026-08-10"
      }
    }
  ],
  "watch_next": [
    {
      "type": "working_capital",
      "statement": "Inventory grew more than twice as fast as revenue, increasing the amount of product carried on the balance sheet.",
      "importance": "medium",
      "evidence": "Inventory built faster than revenue: Inventory growth exceeded revenue growth and inventory intensity increased.",
      "source_date": "2026-08-10"
    },
    {
      "type": "m_and_a",
      "statement": "Six-month cost growth included asset acquisition costs related to AXS-20, partly offset by lower AXS-05 spending.",
      "importance": "medium",
      "evidence": "The increase for the six months period was primarily due to asset acquisition costs related to AXS-20, which were partially offset by lower spending on AXS-05, driven by the timing of clinical study activities.",
      "source_date": "2026-08-10"
    },
    {
      "type": "interest_rates",
      "statement": "Lower interest expense was partly offset by lower interest income from lower interest rates.",
      "importance": "medium",
      "evidence": "The decrease was due to lower interest expense from the Blackstone Loan Agreement, which was partially offset by less interest income from lower interest rates.",
      "source_date": "2026-08-10"
    }
  ],
  "related_tickers": [
    "AXSM"
  ],
  "disclaimer": "Descriptive reporting of filed results. Not investment advice, and contains no forecast or recommendation."
}